Browse articles from EyeWorld.org related to ASCRS. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.

Importance of advocacy—ASCRS helps score big win for glaucoma surgery

Glaucoma surgeons recently faced a potentially disastrous reimbursement situation when five Medicare Administrative Contractors proposed and finalized limiting coverage of several MIGS procedures. Because of extensive advocacy efforts, it was announced that there would be no change in the coverage at this time.

Comments Off on Importance of advocacy—ASCRS helps score big win for glaucoma surgery

Innovator’s Lecture preview

David F. Chang, MD, will deliver the Charles D. Kelman, MD, Innovator’s Lecture during the ASCRS Annual Meeting. Dr. Chang’s lecture will introduce the concept of “frugal innovation,” which involves coming up with ways to deliver quality care either less expensively or by using fewer resources.

Comments Off on Innovator’s Lecture preview

Lindstrom Lecture preview

Renato Ambrósio Jr., MD, PhD, will present the 2024 Richard L. Lindstrom, MD, Medal Lecture at the ASCRS Annual Meeting. Dr. Ambrósio’s lecture will highlight the positive influence of refractive surgery on the developments related to diagnostics and management of corneal ectatic diseases.

Comments Off on Lindstrom Lecture preview

EyeWorld Weekly, March 8, 2024

➤ FDA approves new drug for postop inflammation and pain ➤ Primary endpoints in unadjusted population not met in Phase 3 trial for dry eye drop ➤ Study links inherited eye diseases to gut bacteria ➤ Acquisitions and other news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, March 8, 2024

EyeWorld Weekly, February 9, 2024

➤ FDA warns against copycat eye drops ➤ Generic drop receives FDA approval ➤ Topline data revealed in two presentations ➤ New 72-week data from Phase 3 RVO treatment studies ➤ First patient dosed in Phase 2/3 trial for GA treatment ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, February 9, 2024